Jun 20, 2024, 10:10
Date of improved response rates in mantle cell lymphoma patients
MD Anderson Cancer Center shared on LinkedIn:
“Adding the BTK inhibitor acalabrutinib to chemoimmunotherapy shows improved response rates in mantle cell lymphoma patients, according to primary data presented by our Dr Michael Wang at the 2024 European Hematology Association Annual General Meeting.
See more research presented by our experts at EHA2024.”
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Dec 21, 2024, 13:46
Dec 21, 2024, 13:40
Dec 21, 2024, 13:33
Dec 21, 2024, 13:20
Dec 21, 2024, 13:12